GU Cancers 2022 | Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Prantik Das
• 18 Feb 2022
Prantik Das, MBBS, MRCP, FRCR, PG Dip, UHDB NHS Foundation Trust, Derby, UK and University of Nottingham, Nottingham, UK, discusses a real-world multicenter study comparing atezolizumab and pembrolizumab in advanced or metastatic urothelial carcinoma. 112 patients, who are either ineligible for platinum-based chemotherapy or have progressed on it, were treated with either pembrolizumab or atezolizumab. Both drugs were reported to be well-tolerated, and the data suggest that patients achieved better responses with pembrolizumab than atezolizumab, but not by a statistically significant amount. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
